Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE (Q85931794)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Xavier Montalban

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

Ralf Gold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

Bruce A C Cree

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Bianca Weinstock-Guttman

10

object named as

Bianca Weinstock-Guttman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Michael Kaufman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Robert J Fox

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Hans-Peter Hartung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Douglas Jeffery

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ludwig Kappos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Barry Ticho

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Petra Duda

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Amy Pace

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Denise Campagnolo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

9 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

262

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

326-336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25381458%20AND%20SRC:MED&resulttype=core&format=json

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

22 February 2020

cites work

1 reference

12 December 2020

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

12 December 2020

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

12 December 2020

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

1 reference

12 December 2020

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

12 December 2020

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

1 reference

12 December 2020

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

1 reference

12 December 2020

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

1 reference

12 December 2020

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

1 reference

12 December 2020

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

12 December 2020

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

1 reference

12 December 2020

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

1 reference

12 December 2020

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

1 reference

12 December 2020

Switching from natalizumab to fingolimod: an observational study

1 reference

12 December 2020

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

12 December 2020

Lethal multiple sclerosis relapse after natalizumab withdrawal

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Observations during an elective interruption of natalizumab treatment: a post-marketing study

1 reference

12 December 2020

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis

1 reference

12 December 2020

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

1 reference

12 December 2020

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

12 December 2020

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

1 reference

12 December 2020

Natalizumab dosage suspension: are we helping or hurting?

1 reference

12 December 2020